邁博藥業-B(02181.HK)年度虧損收窄至1.85億元
格隆匯3月26日丨邁博藥業-B(02181.HK)發佈公吿,截至2020年12月31日止年度,公司其他收入3223.7萬元人民幣,同比增長79.1%;期間虧損1.85億元,上年同期虧損2.03億元;每股虧損0.04元。
集團的在研藥物研發開支由上年度的約人民幣1.34億元減少10.3%至該年度的約人民幣1.2億元。減少主要由於我們已於2019年末完成CMAB008的臨牀試驗,並大體完成CMAB007的病例招募,導致合約成本及原材料成本下降所致。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.